ABBV Stock Recent News

ABBV LATEST HEADLINES

ABBV Stock News Image - investopedia.com

Major U.S. equities indexes were mixed on the first day of a new trading week that will feature earnings reports from a slew of major corporations.

investopedia.com 2025 Apr 28
ABBV Stock News Image - globenewswire.com

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).

globenewswire.com 2025 Apr 28
ABBV Stock News Image - fool.com

Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.

fool.com 2025 Apr 28
ABBV Stock News Image - prnewswire.com

NEW YORK , April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

prnewswire.com 2025 Apr 28
ABBV Stock News Image - fool.com

Nearly everything looked great with AbbVie's (ABBV 3.10%) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease drugs Skyrizi and Rinvoq.

fool.com 2025 Apr 28
ABBV Stock News Image - seekingalpha.com

As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its oncology, neuroscience, and immunology franchises. So, total sales of Rinvoq and Skyrizi reached $5.14 billion in the first three months of 2025, increasing by 65.8% year-on-year.

seekingalpha.com 2025 Apr 27
ABBV Stock News Image - fool.com

It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.

fool.com 2025 Apr 26
ABBV Stock News Image - fool.com

A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie (ABBV 3.10%) stock an investor darling on Friday. The pharmaceutical company's performance pushed its stock to a more than 3% gain on the day, well higher than the 0.6% bump of the bellwether S&P 500 index it's a part of.

fool.com 2025 Apr 25
ABBV Stock News Image - seekingalpha.com

AbbVie Inc. beat first-quarter revenue and EPS estimates and raised the full-year EPS guidance by $0.10 and revenue guidance by $700 million. Skyrizi and Rinvoq drove the ABBV Q1 beat with exceptional growth, leading to increased full-year revenue net sales guidance for both drugs. The immunology and neuroscience segments showed robust performance, supporting a bullish outlook, while Humira, the aesthetics, and eye care segments remain weak spots.

seekingalpha.com 2025 Apr 25
ABBV Stock News Image - seekingalpha.com

AbbVie Inc.'s Q1 2025 results exceeded expectations on the earnings front, but the key question is whether the stock is an immediate buy. It saw an accelerated 8.4% YoY revenue growth, driven by strong performance from immunology. Earnings also surprised positively, leading to an upgrade in full-year guidance. Despite this, though, the forward non-GAAP P/E ratio at 15x looks rich compared to both past averages and a comparison with peers.

seekingalpha.com 2025 Apr 25
10 of 50